Background: D-3-aminoisobutyrate, an intermediary product of thymine, is converted to 2-methyl-3-oxopropanoate using pyruvate as an amino acceptor by D-3-aminoisobutyrate-pyruvate aminotransferase (D-AIB AT; EC 2.6.1.40). A large amount of D-AIB AT is distributed in the kidney and liver; however, small amounts are found in the brain. Recently, D-AIB AT was reported to metabolize asymmetric dimethylarginine (ADMA) in vivo and was suggested to be an important enzyme for nitric oxide metabolism because ADMA is a competitive inhibitor for nitric oxide synthase. In this study, we examined the distribution of D-AIB AT in the rat brain further to understand its role. We measured D-AIB AT mRNA and protein expression using quantitative RT-PCR and Western blotting, and monitored its distribution using immunohistochemical staining.
Background D-3-aminoisobutyrate-pyruvate aminotransferase (D-AIB AT, R-3-amino-2-methylpropionate-pyruvate aminotransferase, EC 2.6.1.40, alanine: glyoxylate aminotransferase 2, EC 2.6.1.44) is a unique aminotransferase that metabolizes not L-but the D-isomer of 3-aminoisobutyrate (AIB) as an amino donor and pyruvate as an amino acceptor to generate 2-methyl-3-oxopropanoate and alanine. We, as well as others, have previously purified and characterized D-AIB AT in the rat liver [1, 2] , and its gene structure was determined by Matsui-Lee et al. [3] . The condition resulting in high amounts of D-AIB excretion in the urine is inherited in an autosomal recessive fashion [4] , and individuals with this condition have been reported to lack D-AIB AT activity [5] . D-AIB is an intermediate product of thymine, and D-AIB AT is the only enzyme that metabolizes D-AIB (Kakimoto et al. [5, 6] ). High amounts of D-AIB AT are distributed in the kidney and liver, and small amounts have been identified in the brain. However, no functional reason for D-AIB AT expression in the central nervous system has been identified [7] . D-AIB AT is also known to be a dimethylarginine-pyruvate aminotransferase ( [8] , see Figure 1 ), which metabolizes asymmetric dimethylarginine (ADMA) in vivo [9] . Therefore, it appears that D-AIB AT is also an important enzyme for nitric oxide metabolism because ADMA is a competitive inhibitor of the nitric oxide synthase (NOS) enzyme family [10] . Endothelial (eNOS) and neuronal (nNOS) play an obligatory role in the regulation of cerebral blood flow and cell viability, and in the protection of nerve cells or fibers against pathogenic factors associated with Alzheimer's disease, Huntington's disease, seizures, and migraines [11] . Therefore, in this study, we monitored the mRNA and protein expression of D-AIB AT in the rat brain.
Methods

Experimental animals
Male Wistar rats (CLEA Japan, Tokyo, Japan), 6-8 weeks old, were housed in air-conditioned rooms (temperature, 22 ± 2°C) with a 12-h light-dark cycle. After rats were anaesthetized with 30 ml of diethyl ether and decapitated, the brain was removed and tissues used for examination (frontal cortex, temporal cortex, cerebellum striatum, thalamus, hippocampus, midbrain, pons, and olfactory bulb) were dissected. All experiments were approved by the Ethics Review Committee for Animal Experimentation of Ehime University.
RNA extraction and quantitation of D-AIB AT mRNA expression
We examined ten rat (the ages of rat breakdown was that 6 weeks old is six, 7 weeks old is two and 8 weeks old is two) for RT-PCR. RNA was extracted from each brain region isolated according to the RNeasy Lipid Tissue Mini kit instructions (Qiagen, Valencia, CA, USA), which included DNase treatment (Qiagen). Following assessment of RNA quality and quantity with the NanoDrop (NanoDrop Technologies, DE, USA), 1 μg of total RNA was used for cDNA synthesis with random hexamers using Moloney murine leukemia virus reverse transcriptase (Applied Biosystems, Austin, TX, USA). The expression of the D-AIB AT gene transcript was quantified by real-time PCR with the TaqMan Gene Expression Assay (Applied Biosystems). TaqMan primer-probe sets for D-AIB AT (agxt2, Rn00582928_m1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Ss03375435_u1), used as an endogenous control, were purchased from Applied Biosystems. Quantitative RT-PCR was performed using the StepOnePlus System (Applied Biosystems). Changes in D-AIB AT mRNA expression were calculated after normalization with GAPDH expression. The cDNA from an arbitrarily selected control rat were used as a calibrator sample. The ΔΔCT method provided a relative quantification ratio according to the calibrator, which allowed statistical comparisons of gene expression among samples. Values of fold changes in the sample versus the frontal cortex samples represented averages from triplicate measurements. Statistical calculations were carried out using the SPSS Statistical Software Package 11.5 (SPSS, Tokyo, Japan). The mRNA expression differences among brain tissues were analyzed by analysis of variance with repeated measures followed by the Bonferroni post hoc test. A P value less than 0.05 was considered statistically significant.
Western blotting
We examined four rat (all ages of rat is 6 weeks old) for Western blotting. Brain tissue was homogenized in lysis buffer containing 8.1 mM Na 2 HPO 4 , 2.68 mM KCl, 1.47 mM KH 2 PO 4 , 137 mM NaCl, 1 mM EDTA, and 2 mM 2-mercaptoethanol. Homogenates were centrifuged at 16,000 g for 20 min at 4°C. The supernatant was decanted into a new centrifuge tube. Protein concentrations for each brain region were determined using the BCA Protein Assay Kit (Thermo Fisher Scientific K.K., Yokohama, Japan). Protein samples (10 μg) were suspended in Laemmli sample buffer, and sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis was performed according to standard procedures. Total lysates were separated on 1% SDS-polyacrylamide gels, and were blotted onto polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). After blocking with Blocking One (Nacalai Tesque, Kyoto, Japan), the membranes were incubated with either anti-D-AIB AT rabbit polyclonal primary antibody (specificity of antibody show Additional files 1 and 2) generated using the D-AIB-AT peptide 'SPYTLGLTNVGIYKMEL' (Japan Bioserum, Hiroshima, Japan), or anti-GAPDH rabbit primary antibody (internal control; Abcam, Cambridge, UK) diluted in 1% (v/v) Tween 20 at room temperature for 3 h. Membranes were treated with anti-rabbit goat IgG horseradish peroxidase-linked Whole Antibody (GE Healthcare, Buckinghamshire, UK) diluted in 1% (v/v) Tween 20 at room temperature for 1 h. Visualization using ChemiDoc MP (Bio Rad) was used for detection. Image J (http://rsb.info.nih.gov/ij/index.html) was used for Western blot analysis following digitization.
D-AIB AT immunohistochemistry
Wistar rat brains on postnatal day 7, 14, 28, and 56 were used in this study. Animals were anesthetized by intraperitoneal injection of chloral hydrate (10 mg/kg) and then perfused transcardially with physiological saline, followed by 4% (w/v) paraformaldehyde in 100 mM phosphate buffer (pH 7.4). Brains were removed and post-fixed in the same solution for 12 h at 4°C and embedded in paraffin wax. Frontal sections of rat brains were cut at 5 μm, dewaxed in xylene, and rehydrated with a graded series of ethanol solutions. Histochemistry was performed using the anti-D-AIB AT antibody (this antibody same as Western) in combination with the avidin-biotin peroxidase complex (ABC) method using the VECTASTAIN ABC kit (Vector Labs, Burlingame, CA, USA). Endogenous peroxidase was blocked in methanolic hydrogen peroxidase at 36°C for 30 min, and nonspecific protein binding was suppressed by incubation with 1% (w/v) bovine serum albumin at 36°C for 30 min, followed by rinsing with 0.02 M phosphate-buffered saline (PBS; pH 7.4). Sections were incubated with the anti D-AIB AT antibody at 4°C overnight. After rinsing with PBS, the sections were further incubated with the VEC-TASTAIN ABC reagent at room temperature for 30 min. Finally, the sections were colorized with PBS containing 0.006% (w/v) 3-3-diaminobenzidine tetrahydrochloride and 0.003% (v/v) H 2 O 2 at room temperature for 30 min, and lightly counterstained with hematoxylin.
Results
D-AIB AT mRNA expression in the rat brain compared with GAPDH mRNA expression, used as an internal standard, is shown in Figure 2 . D-AIB AT mRNA was ubiquitously distributed in rat brain tissues. The mRNA expression in the brain cortices, striatum and hippocampus were relatively high when compared with other brain regions but there were no significant differences in expression levels.
D-AIB AT protein levels were measured by Western blotting (Figure 3 ). Protein levels of D-AIB AT in various brain regions were compared with GAPDH. Expression levels in parts of the midbrain (about five fold), hippocampus and olfactory bulb (about three fold) were high when compared with frontal cortex.
Immunohistochemical studies revealed that hippocampus is clearly stained with rabbit anti D-AIB AT antibody (Figure 4b , compared with Figure 4a ; pre-immune rabbit serum). In the hippocampus, neurons in the CA1, CA3, CA4, and dentate gyrus were strongly stained, particularly the cytosolic region. The expression in the cerebral cortex was weaker in the outer layer ( Figure 4c ) than that in deep layers (Figure 4d ). Neurons of the brainstem were also strongly stained (Figure 4e ). Compared with other cortical regions, the retrosplenial cortex was strongly stained (Figure 4f ) . The rat which we examined about each brain tissues is 8 weeks old. During development ( Figure 5 ; day 7 to 56 post partum), D-AIB AT protein was highly expressed in the hippocampus, cortex, and choroid plexus at all ages.
Discussion
To our knowledge, this is the first report to examine the distribution of D-AIB AT in the rat brain. D-AIB AT was distributed in examined-just the regions, with expression being greatest in deep layers of the cortex, hippocampus, and brain stem. Immunohistochemistry revealed that D-AIB AT expression was highest in the retrosplenial cortex, hippocampus, brain stem, and choroid plexus.
High amounts of D-AIB AT are distributed in the kidney and liver [5] , and small amounts are observed in various regions of the brain [7] . Although the only known role of D-AIB AT relates to the metabolism of D-AIB, its precise function in the central nervous system remains unclear. Recently, D-AIB AT was identified as an enzyme that not only catalyzes the metabolism of D-AIB but also catalyzes the degradation of ADMA, which is a competitive inhibitor of NOS [12] . ADMA is present in the central nervous system [13] and is reported to be ubiquitously distributed in various regions of the brain [14] . D-AIB AT inhibits NO production in vitro [10] and actively degrades ADMA in vivo [9] ; however, ADMA is also degraded by dimethylarginine dimethylaminohydrolase (DDAH) 1, a member of the DDAH enzyme family [15] . We hypothesize that D-AIB AT in the brain effectively metabolizes ADMA as an ADMA: pyruvate aminotransferase, an aminotransferase that catalyzes ADMA with pyruvate to form α-keto-δ-(N G ,N G -dimethyl-guanidino) valeric acid and alanine in vivo (Figure 1) , resulting in a decrease to ADMA brain levels, which helps NOS improve endothelial NO production in the brain. In this study, we report that D-AIB AT is distributed in the examined-just the regions. Several studies support the idea that ADMA may be important regulator of the NO system, where elevated ADMA concentrations are associated with hypertension [16] , congestive heart failure [17] , progression of chronic kidney disease [18] and atherosclerosis [19] . D-AIB AT may be related to the vulnerability for cerebro-vascular disease.
Our immunohistochemical studies revealed that D-AIB AT is widely expressed in the retrosplenial cortex and hippocampus. The rat retrosplenial cortex is similar to Brodmann areas 29 and 30 in primates, which has abundant reciprocal projections with the hippocampus directly and indirectly [20] . Inactivation of the retrosplenial cortex is reported to impair active navigation in dark testing conditions in a rat model with tetracaine anesthetization of the retrosplenial cortex, suggesting that this region is important for spatial memory [21] . Hippocampal atrophy is known to be one of the main symptoms of Alzheimer's disease (AD), and disruption of frontohippocampal connections, not only directly but indirectly through damage of the retrosplenial posterior cingulate cortex, is observed in AD [22] . Metabolic decline in the retrosplenial cortex is also reported in AD following positron emission tomography [23, 24] . Pathological changes in this region can also occur in schizophrenia, bipolar disorder, and post-traumatic stress disorder review [25] . Therefore the expression of D-AIB AT in brain lesions formed following neurological disease progression.
Conclusion
In conclusion, D-AIB AT is widely distributed in the brain and may work as an aminotransferase not only related to degradation of D-AIB from thymine. Further studies will be needed to clarify the role of D-AIB in the central nervous system.
Additional files
Additional file 1: The ELISA data of rabbit anti D-AIB AT antibody. The titer of the antibody was assessed by enzyme-linked immunosorbent assay. ◆; pre-immune rabbit serum, ■; anti-D-AIB AT antibody.
Additional file 2: Western blot of rat brain tissues indicates the comparison between rabbit pre-immune serum (left; × 1000) and anti D-AIB antibody (right; × 1000). 
